Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that on July 10, 2026, the Compensation Committee of its Board of Directors granted inducement equity grants covering an aggregate of 41,600 ...
Detailed price information for Travere Therapeutics Inc (TVTX-Q) from The Globe and Mail including charting and trades.
Detailed price information for Ultragenyx Pharmaceu (RARE-Q) from The Globe and Mail including charting and trades.
EVEREST MED (01952.HK) announced that, in relation to the exclusive licensing and collaboration agreement signed with Travere ...
Recently published Alport Syndrome Market Insights report includes a comprehensive understanding of current treatment practices, Alport syndrome emerging drugs, market share of individual therapies, ...
June 2026 saw drug development in oncology and neurology continue and biotech deals over small molecules and RNA therapies ...
Food - Allergen - Peanut Distribution: British ColumbiaOntarioQuebec See the affected products and product photos for this ...
AttivoERP, a full-service Enterprise Resource Planning (ERP) consulting and implementation firm serving manufacturers, ...
With combination therapies and multiple treatment options available for patients, nephrology is in a “therapeutic revolution, ...
View Ligand Pharmaceuticals Incorporated LGND stock quote prices, financial information, real-time forecasts, and company news from CNN.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results